p53 immunoreactivity in astrocytomas and its relationship to survival
| Autor: | L. R. Bridges, S. Al-Sarraj |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Pathology medicine.medical_specialty Time Factors Adolescent Gene Expression Astrocytoma Central nervous system disease Culture Techniques Glioma medicine Humans Tumour suppressor gene Grade I Astrocytomas Aged Neoplasm Staging Frozen section procedure biology Brain Neoplasms business.industry Antibodies Monoclonal Brain General Medicine Middle Aged medicine.disease Immunohistochemistry Survival Rate Mutagenesis biology.protein Surgery Neurology (clinical) Tumor Suppressor Protein p53 Antibody business |
| Zdroj: | British Journal of Neurosurgery. 9:143-150 |
| ISSN: | 1360-046X 0268-8697 |
| Popis: | p53 is a putative tumour suppressor gene implicated in a wide range of human malignancies. Mutation of p53 gene results in a more stable product and increased quantities of p53 protein in the cell. Thus, unlike the normal situation, mutated p53 is detectable by immunohistochemistry. We stained frozen sections of 74 astrocytomas with two antibodies to p53, PAb 1801 and PAb 421. Overall 18/74 (24%) of astrocytomas showed p53 immunoreactivity. Fifteen of 47 (32%) grade IV were p53 immunopositive, as were 3/16 (19%) grade III, 0/7 (0%) grade II and 0/4 (0%) grade I astrocytomas. These findings are in agreement with previous studies in showing relatively greater numbers of high grade than low grade p53 immunopositive tumours. Although we found an expected difference in survival according to grade, there was no significant difference in survival (p0.1) between p53 immunopositive and immunonegative tumours. We conclude that, whilst p53 undoubtedly plays an important role in the molecular 'chain' leading to malignancy in some astrocytomas, within tumours of comparable grade it does not appear to influence survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |